rheumatology
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Patient-reported outcome measuring disease activity in ankylosing spondylitis and axial spondyloarthropathy. BASDAI >=4 indicates high disease activity.
Score interpretation
Low disease activity (BASDAI <4)
→ Low activity; continue current management; consider tapering if stable
High disease activity (BASDAI >=4)
→ High activity; consider biologic (anti-TNF: adalimumab, etanercept; IL-17 inhibitor: secukinumab)
Very high disease activity (BASDAI >6)
→ Severe active AS; biologic therapy; pain management; physiotherapy; reassess at 12 weeks
Interpretation bands for the BASDAI. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Natalizumab · Disease-Modifying Therapy — MS (Anti-VLA-4 Monoclonal Antibody)
- Inebilizumab (Anti-CD19 — IgG4-Related Disease) · Anti-CD19 Monoclonal Antibody (B-Cell Depleting)
- Trimetazidine · Metabolic Anti-Anginal
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Isotretinoin · Systemic retinoid (Vitamin A derivative) / Anti-acne
- Dapsone · Anti-inflammatory / Antimicrobial
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.